ZXR-2
General Information
DRACP ID DRACP00645
Peptide Name ZXR-2
Sequence FKIGGFIKKLWRSLLA
Sequence Length 16
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Synthetic peptide
Classification
Active ACP
Activity Information
Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
---|---|---|---|---|---|---|
HeLa | Human papillomavirus-related endocervical adenocarcinoma | Carcinoma | IC50=8.1±1.6 μM | MTT assay | 2h | 1 |
PC-3 | Prostate carcinoma | Carcinoma | IC50=14.8±1.6 μM | MTT assay | 2h | 1 |
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity HEK293T: IC50=10.1±3.0 μM; WPMY-1: IC50=10.2±2.6 μM
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C93H149N23O18
Absent amino acids CDEHMNPQTVY
Common amino acids KL
Mass 214509
Pl 11.92
Basic residues 4
Acidic residues 0
Hydrophobic residues 9
Net charge 4
Boman Index 161
Hydrophobicity 56.88
Aliphatic Index 128.13
Half Life
Mammalian: 1.1 hour
Yeast: 3 min
E.coli: 2 min
Extinction Coefficient cystines 5500
Absorbance 280nm 366.67
Polar residues 3
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 27778166
Title Isoleucine/leucine residues at "a" and "d" positions of a heptad repeat sequence are crucial for the cytolytic activity of a short anticancer lytic peptide
Year 2017
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available